GlassScriptPhysician profile
Cesar A Morales
NPI 1437228731
$5,005.29
in general payments reported to CMS, 2019-2025
31 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $771 · 2021: $929 · 2022: $542 · 2023: $316 · 2024: $601 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $748.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $724.27 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $580.51 | 2019-2025 | Jardiance |
| Abbvie INC. | $464.51 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $329.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $329.28 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $268.09 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $193.27 | 2019-2024 | Eliquis |
| Amgen INC. | $164.36 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $163.11 | 2019-2024 | Mounjaro |
| Astellas Pharma US INC | $119.12 | 2019 | |
| Abbott Laboratories | $111.02 | 2025 | Eterna |
| Kowa Pharmaceuticals America, INC. | $107.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $81.50 | 2019-2020 | |
| Stryker Corporation | $75.04 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $66.87 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $62.96 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $59.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $54.86 | 2020-2022 | |
| Hologic Sales and Service, LLC | $44.20 | 2023 | Aptima, Thinprep 2000 Processor |
| Takeda Pharmaceuticals U.S.A., INC. | $33.55 | 2019 | |
| Allergan, INC. | $28.78 | 2019 | |
| Mylan Specialty L.P. | $28.66 | 2022 | |
| Depuy Synthes Sales INC. | $24.17 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.78 | 2023 | |
| Redhill Biopharma INC. | $23.17 | 2020 | |
| Corcept Therapeutics | $19.81 | 2024 | Korlym |
| Orthogenrx INC. | $19.81 | 2020 | |
| Roche Diabetes Care, INC. | $17.59 | 2022 | |
| Viatris Specialty LLC | $13.85 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.